

Rubella (German measles) Drug Development Pipeline Study, H2 2018

<https://marketpublishers.com/r/R20CA34CA3AEN.html>

Date: August 2018

Pages: 30

Price: US\$ 1,200.00 (Single User License)

ID: R20CA34CA3AEN

Abstracts

Rubella (German measles) Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Rubella (German measles) pipeline products.

DISEASE OVERVIEW

Rubella virus is one of the key types of infectious conditions causing birth defects. Further, annually, over 100,000 children are born with congenital rubella syndrome (CRS). Africa and South East Asia report incidences of Rubella infection cases. Successful vaccination has restricted the spread of Rubella. However, limited drug therapy options exist for the treatment.

Mild fever and headache, large lymph nodes and rashes are common symptoms of Rubella but these often appear after two to three weeks of being infected.

Due to low costs, the returns for vaccines are much higher. Accordingly, five companies are working on developing vaccines for Rubella. Biological E Limited, GlaxoSmithKline Plc, Indian Immunologicals Ltd, Japan Vaccine Co Ltd and Zydus Cadila are currently working on developing new therapeutic compounds for treatment or prevention of Rubella.

REPORT DESCRIPTION

The Rubella (German measles) pipeline guide presents complete overview of drugs currently being developed for Rubella (German measles). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery,

NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Rubella (German measles) pipeline candidate.

Research and Development progress along with latest news related to each of the Rubella (German measles) pipeline candidates is included.

Major companies participating in therapeutic development of Rubella (German measles) are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Rubella (German measles) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Rubella (German measles) clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Rubella (German measles) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF RUBELLA (GERMAN MEASLES) PIPELINE REPORT INCLUDES

Panorama of Rubella (German measles) pipeline markets including statistics on therapeutic drugs and companies involved

Rubella (German measles) Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered

Rubella (German measles) pipeline candidates across various 'Mechanism of Actions' are also presented in the study

Overview of companies participating in Rubella (German measles) pipeline with short introduction to their businesses and pipeline projects

For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.

Research and Development progress and trial details, results wherever available, are also included in the pipeline study

The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Rubella (German measles) pipeline therapeutics

REASONS TO BUY

Get clear understanding of the entire Rubella (German measles) pipeline, with details on active projects

Get in detail information of each product with updated information on each project along with key milestones

Know the list of companies participating in global Rubella (German measles) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

Contents

I. KEY FINDINGS

1. Companies Investing in Rubella Pipeline include-
 - Number of Companies with Rubella projects in pre-clinical Development-
 - Number of Companies with Rubella projects in Clinical Development-
 - Rubella Pipeline Companies based in Americas
 - Rubella Pipeline Companies based in Europe
 - Rubella Pipeline Companies based in Asia Pacific
 - Rubella Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
 - Rubella Pipeline Agents in pre- clinical/Discovery stage of Development
 - Rubella Pipeline Agents in Clinical Development stage
 - Rubella Pipeline Therapeutic Compounds received special status
 - Mechanism of Action of most pipeline Drugs-
 - Small molecules among the Rubella Pipeline agents

II. INSIGHTS INTO RUBELLA PIPELINE

1. Disease Overview
 - Introduction to Rubella
 - Symptoms and Causes of Rubella
 - Treatment or Prevention Options for Rubella
 - Other Details
2. Phase wise Pipeline Compounds
 - Rubella Pipeline- Pre- Clinical/Discovery stage Drugs
 - Rubella Pipeline- Phase 1 stage Drugs
 - Rubella Pipeline- Phase 2 stage Drugs
 - Rubella Pipeline- Phase 3 stage Drugs
 - Rubella Pipeline- Pre-Registration stage Drugs
3. Company wise Rubella Pipeline Compounds
4. Rubella Pipeline by Mechanism of Action

III. RUBELLA PIPELINE COMPOUND DETAILS

measles-rubella (MR) vaccine
measles(Schwarz)-mumps(RIT 4385)-rubella(Wistar RA 27/3) vaccine
Measles Rubella Vaccine

VN-0102

Measles-Mumps-Rubella-Varicella vaccine

Drug Details

1. Snapshot

Name of the Therapeutic Agent

Originator

Developing Company

Co-Developer/License Partner

Orphan Drug/Fast Track/Designation

Development Phase

2. Drug Overview

3. Mechanism of Action

4. Current Status

5. Clinical Trial Details

IV. RUBELLA PIPELINE COMPANY BRIEFS

Biological E Limited

GlaxoSmithKline Plc

Indian Immunologicals Ltd

Japan Vaccine Co Ltd

Cadila Healthcare Ltd

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL RUBELLA PIPELINE MARKET

VI. APPENDIX

1. Publisher's Expertise

2. Research Methodology

3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability

I would like to order

Product name: Rubella (German measles) Drug Development Pipeline Study, H2 2018

Product link: <https://marketpublishers.com/r/R20CA34CA3AEN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R20CA34CA3AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970